ImmunityBio, Inc. (IBRX) — Financial statements
Income statement, balance sheet, and cash flow for ImmunityBio, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 113↑668.3% | 15↑2270.6% | 0.62↑159.2% | 0.24↓74.3% | 0.93 | |
| Cost of Revenue | 0.75 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 113↑663.2% | 15↑2270.6% | 0.62↑159.2% | 0.24↓74.3% | 0.93 | |
| Operating Expenses | ||||||
| R&D Expenses | 208↑9.3% | 190↓18.2% | 232↓6.4% | 248↑26.6% | 196 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 147↓12.8% | 169↑30.2% | 130↑26.2% | 103↓24.1% | 135 | |
| Other Expenses | 14 | 0.00↓100.0% | 0.89↑30.1% | 0.68 | 0.00 | |
| Operating Expenses | 369↑2.7% | 359↓1.1% | 363↑3.2% | 352↑6.1% | 331 | |
| Total Costs & Expenses | 369↑2.9% | 359↓1.1% | 363↑3.2% | 352↑6.1% | 331 | |
| Operating Results | ||||||
| Operating Income | -256↑25.6% | -344↑5.0% | -362↓3.1% | -351↓6.4% | -330 | |
| Depreciation & Amortization | 16↓11.6% | 18↓5.2% | 19↑1.4% | 18↑28.2% | 14 | |
| EBITDA | -224↑15.5% | -264↑44.8% | -479↓36.0% | -352↓9.7% | -321 | |
| EBIT | -239↑15.2% | -282↑43.3% | -497↓34.3% | -370↓10.5% | -335 | |
| Interest & Other Income | ||||||
| Net Interest Income | -106↑18.1% | -129↓50.6% | -86↓93.2% | -44↓217.1% | -14 | |
| Interest Income | 7↑179.0% | 2↑178.1% | 0.86↓68.1% | 3↑223.9% | 0.84 | |
| Interest Expense | 113↓14.5% | 132↑51.8% | 87↑83.9% | 47↑217.5% | 15 | |
| Non-Operating Income | -17↑72.8% | -62↓146.1% | 135↑616.0% | 19↑300.1% | 5 | |
| Other Income / Expenses | -96↓37.6% | -69↑68.7% | -222↓235.9% | -66↓237.4% | -20 | |
| Income Before Tax | -352↑15.0% | -414↑29.2% | -584↓39.9% | -417↓19.3% | -350 | |
| Income Tax Expense | -0.14 | 0.00↑100.0% | -0.04↓217.6% | 0.03↑277.8% | 0.01 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -351↑15.0% | -414↑29.2% | -584↓39.9% | -417↓19.3% | -350 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -351↑15.0% | -414↑29.1% | -583↓40.0% | -417↓20.1% | -347 | |
| Bottom-Line Net Income | -351↑15.0% | -414↑29.1% | -583↓40.0% | -417↓20.1% | -347 | |
| EPS (Basic) | -0.38↑35.6% | -0.59↑48.7% | -1.15↓10.6% | -1.04↓16.9% | -0.89 | |
| EPS (Diluted) | -0.38↑38.7% | -0.62↑46.1% | -1.15↓10.6% | -1.04↓16.9% | -0.89 | |
| Weighted Average Shares | 920↑31.9% | 697↑37.1% | 509↑27.2% | 400↑2.7% | 389 | |
| Weighted Average Diluted Shares | 920↑31.3% | 700↑37.7% | 509↑27.2% | 400↑2.7% | 389 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.